PURPOSE: Decitabine is a nucleoside analog used in the treatment for myelodysplastic syndrome. The compound requires intracellular conversion to its triphosphate to become active. Decitabine triphosphate has, however, never been quantified in peripheral blood mononuclear cells (PBMCs) from patients. METHOD: This article describes a method for the quantitative determination of decitabine triphosphate in PBMCs using liquid chromatography coupled to tandem mass spectrometry. The method was applied to ex vivo incubated whole blood samples and samples from three patients receiving prolonged low-dose decitabine treatment. RESULTS: We successfully quantitated decitabine triphosphate in PBMCs. Considerable levels were detected in PBMCs from two patients that responded well to therapy, whereas only low levels were present in a non-responding patient. Moreover, the data show that, in contrast to plasma decitabine, intracellular decitabine triphosphate accumulates during a treatment cycle of nine infusions at a dose of 15 mg/m(2). CONCLUSIONS: The results suggest a relationship between decitabine triphosphate levels and response to therapy. Based on the observed accumulation of decitabine triphosphate during a treatment cycle, a less intensive dose scheme could be feasible.
PURPOSE:Decitabine is a nucleoside analog used in the treatment for myelodysplastic syndrome. The compound requires intracellular conversion to its triphosphate to become active. Decitabine triphosphate has, however, never been quantified in peripheral blood mononuclear cells (PBMCs) from patients. METHOD: This article describes a method for the quantitative determination of decitabine triphosphate in PBMCs using liquid chromatography coupled to tandem mass spectrometry. The method was applied to ex vivo incubated whole blood samples and samples from three patients receiving prolonged low-dose decitabine treatment. RESULTS: We successfully quantitated decitabine triphosphate in PBMCs. Considerable levels were detected in PBMCs from two patients that responded well to therapy, whereas only low levels were present in a non-responding patient. Moreover, the data show that, in contrast to plasma decitabine, intracellular decitabine triphosphate accumulates during a treatment cycle of nine infusions at a dose of 15 mg/m(2). CONCLUSIONS: The results suggest a relationship between decitabine triphosphate levels and response to therapy. Based on the observed accumulation of decitabine triphosphate during a treatment cycle, a less intensive dose scheme could be feasible.
Authors: Yogen Saunthararajah; Mikkael Sekeres; Anjali Advani; Reda Mahfouz; Lisa Durkin; Tomas Radivoyevitch; Ricki Englehaupt; Joy Juersivich; Kathleen Cooper; Holleh Husseinzadeh; Bartlomiej Przychodzen; Matthew Rump; Sean Hobson; Marc Earl; Ronald Sobecks; Robert Dean; Frederic Reu; Ramon Tiu; Betty Hamilton; Edward Copelan; Alan Lichtin; Eric Hsi; Matt Kalaycio; Jaroslaw Maciejewski Journal: J Clin Invest Date: 2015-01-26 Impact factor: 14.808
Authors: Hongyan Wang; Ping Chen; Jiang Wang; Ramasamy Santhanam; Josephine Aimiuwu; U V Vijaya Saradhi; Zhongfa Liu; Sebastian Schwind; Alice Mims; John C Byrd; Michael R Grever; Miguel A Villalona-Calero; Rebecca Klisovic; Alison Walker; Ramiro Garzon; William Blum; Kenneth K Chan; Guido Marcucci Journal: AAPS J Date: 2012-11-22 Impact factor: 4.009
Authors: Simin Öz; Günter Raddatz; Maria Rius; Nadja Blagitko-Dorfs; Michael Lübbert; Christian Maercker; Frank Lyko Journal: Nucleic Acids Res Date: 2014-08-26 Impact factor: 16.971
Authors: Sabin Llona-Minguez; Andreas Höglund; Sylvain A Jacques; Lars Johansson; José Manuel Calderón-Montaño; Magnus Claesson; Olga Loseva; Nicholas C K Valerie; Thomas Lundbäck; Javier Piedrafita; Giovanni Maga; Emmanuele Crespan; Laurent Meijer; Estefanía Burgos Morón; Pawel Baranczewski; Ann-Louise Hagbjörk; Richard Svensson; Elisee Wiita; Ingrid Almlöf; Torkild Visnes; Fredrik Jeppsson; Kristmundur Sigmundsson; Annika Jenmalm Jensen; Per Artursson; Ann-Sofie Jemth; Pål Stenmark; Ulrika Warpman Berglund; Martin Scobie; Thomas Helleday Journal: J Med Chem Date: 2016-01-27 Impact factor: 7.446
Authors: Robert Molokie; Donald Lavelle; Michel Gowhari; Michael Pacini; Lani Krauz; Johara Hassan; Vinzon Ibanez; Maria A Ruiz; Kwok Peng Ng; Philip Woost; Tomas Radivoyevitch; Daisy Pacelli; Sherry Fada; Matthew Rump; Matthew Hsieh; John F Tisdale; James Jacobberger; Mitch Phelps; James Douglas Engel; Santhosh Saraf; Lewis L Hsu; Victor Gordeuk; Joseph DeSimone; Yogen Saunthararajah Journal: PLoS Med Date: 2017-09-07 Impact factor: 11.069
Authors: A Unnikrishnan; A N Q Vo; R Pickford; M J Raftery; A C Nunez; A Verma; L B Hesson; J E Pimanda Journal: Leukemia Date: 2017-11-29 Impact factor: 11.528